include PKU and congenital hypothyroidism, but additional tests vary from state to state. The American Academy of Pediatrics and the Maternal and Child Health Bureau sponsored a Task Force on NBS to consider national standards for inclusion of diseases in NBS and criteria for evaluation of new diseases and new technologies. Molecular genetic testing is used as a follow-up test for sickle cell disease NBS, providing confirmation from the original NBS blood blotters. New screening tests include tandem mass spectrometry, which is capable of quantitating a large number of analytes A critical issue will be to determine which should be reported. Only four states test for cystic fibrosis (CF) at this time, but other states are planning CF pilot screening. Mutation screening for CF is another example of molecular follow-up testing for a positive newborn screen. Another new disease that is being added to the NBS battery is congenital adrenal hyperplasia with testing for elevated serum 17-hydroxyprogesterone. DNA confirmation helps to determine which infants have severe disease and require immediate treatment. Initial hearing screening involves physiologic testing in the newborn nursery. However, follow-up testing for connexin 26 mutations is being suggested for nonsyndromic, genetic deafness. Public health genetic screening in neonates is facing new applications and must consider ethical issues accompanying population-based genetic testing.
Adult Genetic Screenins. Are we ready for hemochromatosis? LA Bradlev'. G.E. Palomaki . W. ~urke' and 1.E. Haddow'. 'Foundation for Blood Research, Scarborough, ME, and 'university of Washington, Seattle, WA.
Since the discovery of the HFE gene and two common mutations, clinicians, researchers, and public health policy makers have debated the role of genetic testing in the identification of hereditary hemochromatosis (HI-IC). Wdh provision of appropriate informat~on about benefa and risks of testing, mutation analysis is moving into routine prachce, both as a diagnostic test for persons presenting with biochemical evidence of iron overload or clmical symptoms, and as part of risk assessment in families with a dmgnosed case. Effotts to improve education of health care providers and consumen about HHC and available diagnostic testing are underway. However, HHC is often not recognized before the onset of serious clinical symptoms, and the public health impact of improved diagnosis alone may be limited. HHC is relat~vely common, potentially serious, and preventable with presymptomatlc identification. For these reasons, some within the medical community and patient support groups have advocated immediate implementauon of population screening for HHC. Many others, however, are urging caution until sufficient data are collected through intervention trials, both ongomg and planned, to adequately answer certain key questions, incluhg: I) the penetmce of the disorder by gender and age; 2) the ~mpact of genetlc and environmental modifpg factors; 3) the extent to which certam associated clinical symptoms can be attributed to HHC; 4) the appropriate target populations for screening; and 5) the effectiveness, costs, benefits and risks of different screening strategies. This last question includes collecting info-tion as diverse as whether it is more effective to use mutatlon analysis as the initial screening test or part of diagnostic follow-up, the psychological .ff& of positive screenmg results on 'Aeakhy" persons, whether screen positive md~viduals wlll be compliant over 10-20 or more years of monrtomg andlor phlebotomy treatment, and how data might be collected to assess the ongoing safety and effectiveness of such a screening program HHC would appear to be an ideal model for addressing a range of issues related to the integration of adult genetic screening into routine practice With the completion of the Human Genome Project in the next few years, numerous DNA-based tests will become available in medical practice. Over 700 tests are currently used. An Important challenge for the years to come is the appropriateness of using genetic information in disease prevention, the fundamental mission of public health. Using examples from genetic susceptibility to chron~c diseases, I will discuss three main themes that serve a s the scientific foundation for integrating genetics into disease prevention activities The themes are: I ) human diseases results from the interaction of genetic variation and environmental factors, broadly defined to include physical, chemical, infectious, nutritional, and behaworal factors; 2) there is an urgent need for public health research agenda to define the appropriate medical, behavioral, dietary and environmental interventions that can be targeted to individuals with various genetic backgrounds; 3) the development of genetic tests can then be gulded by evidence-based requirements for clinical validity (calculating positive and negative predictive values of predictive tests) and cllnlcal utility (demonstrat~ng reduction in morbid~ty and morality following testing). Using these themes. I will describe CDC scientific ln~tiatlves to provlde Intramural and extramural support for research in human genome epidemiology, prevention effectiveness, communication research and dissemination of information on genetic tests.
